Dawn Hanna, PA
Medical · Saint Francisville, LANPI 1063454825
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 320 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations.
Across 320 payments — averaging $14.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$937
- Novo Nordisk$787
- GSK$417
- Supernus Pharmaceuticals, Inc.$313
- Pfizer$256
- Teva Pharmaceuticals USA, Inc.$224
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,591100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 96 | $937 |
| Novo Nordisk | 46 | $787 |
| GSK | 26 | $417 |
| Supernus Pharmaceuticals, Inc. | 27 | $313 |
| Pfizer | 15 | $256 |
| Teva Pharmaceuticals USA, Inc. | 16 | $224 |
| Lilly USA, LLC | 12 | $222 |
| Bayer | 6 | $114 |
| Phathom Pharmaceuticals, Inc. | 8 | $107 |
| Sanofi-aventis U.S. LLC | 8 | $107 |
| Tactile Systems Technology Inc | 1 | $106 |
| AstraZeneca | 6 | $103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Smith+Nephew | 4 | $52 |
| Lundbeck LLC | 3 | $47 |
| Astellas Pharma US Inc | 3 | $47 |
| Johnson & Johnson | 3 | $44 |
| Boston Scientific | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 3 | $41 |
| Exact Sciences | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Organon | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Merck | 2 | $36 |
| Amgen | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Novartis | 2 | $28 |
| Dexcom, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Abbott | 1 | $16 |
| Corium, LLC | 1 | $15 |
| Seqirus USA Inc | 1 | $13 |
| Neos Therapeutics, LP | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$125
- Wegovy$125
- Flexitouch Plus$106
- ENTRE$106
How this compares
$4,591 in reported general payments places this provider in the 85th percentile of 253 medical providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 49 | $59,304 |
| OzempicSemaglutide | 54 | $56,698 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $24,393 |
| JardianceEmpagliflozin | 20 | $16,372 |
| RybelsusSemaglutide | 16 | $14,310 |
| FarxigaDapagliflozin Propanediol | 14 | $12,220 |
| EliquisApixaban | 12 | $9,115 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $8,053 |
| LinzessLinaclotide | 13 | $6,993 |
| XareltoRivaroxaban | 11 | $5,893 |
| Pantoprazole Sodium | 167 | $2,062 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $992 |
| Fluconazole | 55 | $917 |
| Cefdinir | 43 | $759 |
| Nadolol | 11 | $733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $787 | $71,00870 claims |
| Lilly USA, LLCMounjaro | $222 | $59,30449 claims |
| GSKTrelegy Ellipta | $417 | $24,39330 claims |
| Boehringer IngelheimJardiance | $19 | $16,37220 claims |
| AstraZenecaFarxiga | $103 | $12,22014 claims |
| PfizerEliquis | $256 | $9,11512 claims |
| AbbVieLinzess, Synthroid | $937 | $7,52328 claims |
| Johnson & JohnsonXarelto | $44 | $5,89311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 253 medical providers in Louisiana.
Other medical in Saint Francisville
- Kristi RobertBaton Rouge$486K
- Vickie RiceBaton Rouge$19K
- Mary McFerrenShreveport$16K
- Rachel RhinehartJefferson$16K
- Sydney FussellCovington$16K
- Thomas BriscoeLafayette$13K
- Seth HendrixShreveport$12K
- Jessica PelusoNatchitoches$12K
- Heather RoanBossier City$11K
- Emily FerraraBaton Rouge$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.